[1]刘魏,童培建,肖鲁伟,等.益骨汤口服联合太极拳锻炼治疗老年性骨质疏松症肾阳虚证[J].中医正骨,2018,30(11):6-12.
　LIU Wei,TONG Peijian,XIAO Luwei,et al.Oral application of Yigu Tang(益骨汤)combined with shadow boxing exercises for treatment of osteoporosis with kidney-yang deficiency syndrome in the aged[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(11):6-12.
点击复制

益骨汤口服联合太极拳锻炼治疗老年性骨质疏松症肾阳虚证()
分享到：

《中医正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第30卷
期数:
2018年11期
页码:
6-12
栏目:
临床研究
出版日期:
2018-11-20

文章信息/Info

Title:
Oral application of Yigu Tang(益骨汤)combined with shadow boxing exercises for treatment of osteoporosis with kidney-yang deficiency syndrome in the aged
作者:
刘魏1; 童培建2; 肖鲁伟2; 何帮剑2
(1.浙江省德清县中医院,浙江 德清 313200; 2.浙江中医药大学附属第一医院,浙江 杭州 310006)
Author(s):
LIU Wei1; TONG Peijian2; XIAO Luwei2; HE Bangjian2
1.Traditional Chinese Medical Hospital of Deqing county,Deqing 310053,Zhejiang,China 2.The First Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou 310006,Zhejiang,China
关键词:
骨质疏松;  肾阳虚;  益骨汤;  太极拳;  生长激素;  胰岛素样生长因子1;  骨密度;  阿仑膦酸钠;  临床试验
Keywords:
osteoporosis;  kidney-yang deficiency;  Yigu Tang;  shadow boxing;  growth hormone;  insulin-like growth factor I;  bone density;  alendronate sodium;  clinical trial
摘要:
目的:观察益骨汤口服联合太极拳锻炼治疗老年性骨质疏松症肾阳虚证的临床疗效,并分析其作用机制。方法:将80例老年性骨质疏松症肾阳虚证患者随机分为2组,每组40例,分别采用益骨汤口服联合太极拳锻炼治疗和钙剂联合阿仑膦酸钠口服治疗。益骨汤水煎服,每日1剂,分2次服用,连续服用6个月; 太极拳每日早晚锻炼1次,每次15～20 min,连续6个月; 碳酸钙D3咀嚼片(Ⅱ)每日口服1次,每次1片,连续服用6个月; 阿仑膦酸钠每周口服1片,连续服用6个月。分别于治疗前和治疗开始后1个月、3个月、6个月,比较2组患者腰背部疼痛视觉模拟量表(visual analogue scale,VAS)评分、临床症状评分以及生长激素(growth hormone,GH)、胰岛素样生长因子-Ⅰ(insulin-like growth factors-Ⅰ,IGF-Ⅰ)血清含量; 并于治疗前和治疗开始后6个月,比较2组患者腰椎骨密度。结果:①腰背部疼痛VAS评分。时间因素和分组因素存在交互效应(F=36.390,P=0.000); 2组患者腰背部疼痛VAS评分总体比较,差异有统计学意义,即存在分组效应(F=7.257,P=0.000); 治疗前后不同时间点腰背部疼痛VAS评分的差异有统计学意义,即存在时间效应(F=2 717.259,P=0.000); 2组患者腰背疼痛VAS评分均呈下降趋势,但2组的下降趋势不完全一致[(6.87±0.34)分,(4.68±0.43)分,(3.45±0.39)分,(1.59±0.36)分,F=1 282.371,P=0.000;(6.79±0.36)分,(5.47±0.27)分,(4.24±0.31)分,(2.54±0.34)分,F=1 547.065,P=0.000]; 治疗前,2组患者腰背部疼痛VAS评分比较,差异无统计学意义(t=-0.946,P=0.347); 治疗开始后 1 个月、3 个月和6个月,益骨汤联合太极拳组VAS评分均低于钙剂联合阿仑膦酸钠组(t=10.029,P=0.000; t=9.925,P=0.000; t=12.148,P=0.000)。②临床症状评分。时间因素和分组因素存在交互效应(F=44.886,P=0.000); 2 组患者临床症状评分总体比较,差异有统计学意义,即存在分组效应(F=10.506,P=0.000); 治疗前后不同时间点临床症状评分的差异有统计学意义,即存在时间效应(F=1 281.241,P=0.000); 2组患者临床症状评分均呈下降趋势,但2组的下降趋势不完全一致[(19.86±1.83)分,(15.66±0.52)分,(12.19±0.68)分,(9.61±0.87)分,F=673.543,P=0.000;(19.89±1.11)分,(17.45±0.68)分,(15.49±0.52)分,(12.68±0.69)分,F=687.054,P=0.000]; 治疗前,2组患者临床症状评分比较,差异无统计学意义(t=0.081,P=0.936); 治疗开始后1个月、3个月和6个月,益骨汤联合太极拳组临床症状评分均低于钙剂联合阿仑膦酸钠组(t=13.036,P=0.000; t=24.324,P=0.000; t=17.380,P=0.000)。③腰椎骨密度。治疗前,2组患者腰椎骨密度比较,差异无统计学意义(t=-0.777,P=0.439); 治疗开始后6个月,2组患者腰椎骨密度均高于治疗前[(0.63±0.12)g·cm-2,(0.86±0.25)g·cm-2,t=-5.246,P=0.000;(0.61±0.11)g·cm-2,(0.74±0.18)g·cm-2,t=-3.897,P=0.000],益骨汤联合太极拳组腰椎骨密度高于钙剂联合阿仑膦酸钠组(t=-2.464,P=0.016)。④GH血清含量。时间因素和分组因素存在交互效应(F=69.456,P=0.000); 2组患者GH血清含量总体比较,差异有统计学意义,即存在分组效应(F=-5.959,P=0.000); 治疗前后不同时间点GH血清含量的差异有统计学意义,即存在时间效应(F=790.502,P=0.000); 2组患者GH血清含量均呈升高趋势,但2组的升高趋势不完全一致[(0.79±0.44)ug·L-1,(2.51±0.77)ug·L-1,(4.10±0.88)ug·L-1,(5.59±1.08)ug·L-1,F=494.694,P=0.000;(0.78±0.47)ug·L-1,(1.44±0.64)ug·L-1,(2.69±0.81)ug·L-1,(3.99±1.03)ug·L-1,F=332.258,P=0.000]; 治疗前,2组患者GH血清含量比较,差异无统计学意义(t=-0.068,P=0.946); 治疗开始后1个月、3个月和6个月,益骨汤联合太极拳组GH血清含量均高于钙剂联合阿仑膦酸钠组(t=-6.742,P=0.000; t=-7.433,P=0.000; t=-6.751,P=0.000)。⑤IGF-Ⅰ血清含量。时间因素和分组因素存在交互效应(F=10.313,P=0.000); 2组患者IGF-Ⅰ血清含量总体比较,差异有统计学意义,即存在分组效应(F=-4.466,P=0.000); 治疗前后不同时间点IGF-Ⅰ血清含量的差异有统计学意义,即存在时间效应(F=380.659,P=0.000); 2组患者IGF-Ⅰ血清含量均呈上升趋势,但2组的上升趋势不完全一致[(178.95±7.59)ug·L-1,(233.96±20.58)ug·L-1,(255.18±22.49)ug·L-1,(296.82±28.29)ug·L-1,F=231.799,P=0.000;(177.12±10.19)ug·L-1,(210.39±17.67)ug·L-1,(232.54±21.01)ug·L-12,(264.98±32.57)ug·L-1,F=163.707,P=0.000]; 治疗前,2组患者IGF-Ⅰ血清含量比较,差异无统计学意义(t=-0.907,P=0.367); 治疗开始后1个月、3个月和6个月,益骨汤联合太极拳组IGF-Ⅰ血清含量均高于钙剂联合阿仑膦酸钠组(t=-5.495,P=0.000; t=-4.652,P=0.000; t=-4.668,P=0.000)。结论:益骨汤口服联合太极拳锻炼与钙剂联合阿仑膦酸钠口服治疗老年性骨质疏松症肾阳虚证,均能在一定程度上缓解腰背部疼痛、改善患者的临床症状和提高患者骨密度,但前者的临床疗效优于后者,其作用机制可能与其能提高患者血清GH、IGF-Ⅰ含量有关。
Abstract:
Objective:To observe the clinical curative effects of oral application of Yigu Tang(益骨汤,YGT)combined with shadow boxing exercises for treatment of osteoporosis with kidney-yang deficiency syndrome in the aged,and to analyze its mechanism of action.Methods:Eighty aged patients with kidney-yang deficiency type osteoporosis were randomly divided into 2 groups,40 cases in each group,and were treated with combination therapy of oral application of YGT and shadow boxing exercises(group A)and combination therapy of oral application of calcium agents and alendronate sodium(group B)respectively.The YGT were taken one dose a day in the morning and evening respectively for consecutive 6 months.The shadow boxing exercises were performed in the morning and evening respectively,15-20 minutes at a time for consecutive 6 months.The Caltrate D tablets were taken once a day,1 tablet at a time for consecutive 6 months.The alendronate sodium tablets were taken once a week,1 tablet at a time for consecutive 6 months.The low back pain visual analogue scale(VAS)scores,the clinical symptom scores and the serum contents of growth hormone(GH)and insulin-like growth factors-Ⅰ(IGF-Ⅰ)were measured and compared between the 2 groups before treatment and at 1,3 and 6 months after the beginning of the treatment respectively,and the lumbar bone mineral density(BMD)was measured and compared between the 2 groups before treatment and at 6 months after the beginning of the treatment.Results:There was interaction between time factor and group factor in low back pain VAS scores(F=36.390,P=0.000).There was statistical difference in low back pain VAS scores between the 2 groups,in other words,there was group effect(F=7.257,P=0.000).There was statistical difference in low back pain VAS scores between different timepoints before and after the treatment,in other words,there was time effect(F=2 717.259,P=0.000).The low back pain VAS scores presented a time-dependent decreasing trend in the 2 groups,while the 2 groups were inconsistent with each other in the decreasing trend of low back pain VAS scores(6.87+/-0.34,4.68+/-0.43,3.45+/-0.39,1.59+/-0.36 points,F=1 282.371,P=0.000; 6.79+/-0.36,5.47+/-0.27,4.24+/-0.31,2.54+/-0.34 points,F=1 547.065,P=0.000).There was no statistical difference in low back pain VAS scores between the 2 groups before treatment(t=-0.946,P=0.347).The low back pain VAS scores were lower in group A compared to group B at 1,3 and 6 months after the beginning of the treatment(t=10.029,P=0.000; t=9.925,P=0.000; t=12.148,P=0.000).There was interaction between time factor and group factor in clinical symptom scores(F=44.886,P=0.000).There was statistical difference in clinical symptom scores between the 2 groups in general,in other words,there was group effect(F=10.506,P=0.000).There was statistical difference in clinical symptom scores between different timepoints before and after the treatment,in other words,there was time effect(F=1 281.241,P=0.000).The clinical symptom scores presented a time-dependent decreasing trend in the 2 groups,while the 2 groups were inconsistent with each other in the decreasing trend of clinical symptom scores(19.86+/-1.83,15.66+/-0.52,12.19+/-0.68,9.61+/-0.87 points,F=673.543,P=0.000; 19.89+/-1.11,17.45+/-0.68,15.49+/-0.52,12.68+/-0.69 points,F=687.054,P=0.000).There was no statistical difference in clinical symptom scores between the 2 groups before treatment(t=0.081,P=0.936).The clinical symptom scores were lower in group A compared to group B at 1,3 and 6 months after the beginning of the treatment(t=13.036,P=0.000; t=24.324,P=0.000; t=17.380,P=0.000).There was no statistical difference in lumbar BMD between the 2 groups before treatment(t=-0.777,P=0.439).The lumbar BMD was higher at 6 months after the beginning of the treatment compared to pretreatment in the 2 groups(0.63+/-0.12 vs 0.86+/-0.25 g/cm(-2),t=-5.246,P=0.000; 0.61+/-0.11 vs 0.74+/-0.18 g/cm(-2),t=-3.897,P=0.000),and was higher in group A compared to group B(t=-2.464,P=0.016).There was interaction between time factor and group factor in serum contents of GH(F=69.456,P=0.000).There was statistical difference in serum contents of GH between the 2 groups in general,in other words,there was group effect(F=-5.959,P=0.000).There was statistical difference in serum contents of GH between different timepoints before and after the treatment,in other words,there was time effect(F=790.502,P=0.000).The serum contents of GH presented a time-dependent increasing trend in the 2 groups,while the 2 groups were inconsistent with each other in the increasing trend of serum contents of GH(0.79+/-0.44,2.51+/-0.77,4.10+/-0.88,5.59+/-1.08 ug/L,F=494.694,P=0.000; 0.78+/-0.47,1.44+/-0.64,2.69+/-0.81,3.99+/-1.03 ug/L,F=332.258,P=0.000).There was no statistical difference in serum contents of GH between the 2 groups before treatment(t=-0.068,P=0.946).The serum contents of GH were higher in group A compared to group B at 1,3 and 6 months after the beginning of the treatment(t=-6.742,P=0.000; t=-7.433,P=0.000; t=-6.751,P=0.000).There was interaction between time factor and group factor in serum contents of IGF-Ⅰ(F=10.313,P=0.000).There was statistical difference in serum contents of IGF-Ⅰ between the 2 groups in general,in other words,there was group effect(F=-4.466,P=0.000).There was statistical difference in serum contents of IGF-Ⅰ between different timepoints before and after the treatment,in other words,there was time effect(F=380.659,P=0.0000).The serum contents of IGF-Ⅰ presented a time-dependent increasing trend in the 2 groups,while the 2 groups were inconsistent with each other in the increasing trend of serum contents of IGF-Ⅰ(178.95+/-7.59,233.96+/-20.58,255.18+/-22.49,296.82+/-28.29 ug/L,F=231.799,P=0.000; 177.12+/-10.19,210.39+/-17.67,232.54+/-21.01,264.98+/-32.57 ug/L,F=163.707,P=0.000).There was no statistical difference in serum contents of IGF-Ⅰ between the 2 groups before treatment(t=-0.907,P=0.367).The serum contents of IGF-Ⅰ were higher in group A compared to group B at 1,3 and 6 months after the beginning of the treatment(t=-5.495,P=0.000; t=-4.652,P=0.000; t=-4.668,P=0.000).Conclusion:Both combination therapy of oral application of YGT and shadow boxing exercises and combination therapy of oral application of calcium agents and alendronate sodium can relieve low back pain,improve patients' clinical symptoms and increase patients'BMD to some extent,however,the former surpasses the latter in clinical curative effects,and its mechanisms of action may be that it can increase the serum contents of GH and IGF-Ⅰ.

参考文献/References:


[1] SI L,WINZENBERG TM,JIANG Q,et al.Projection of osteoporosis-related franctures and costs in China:2010-2050[J].Osteoporosis International,2015,26(7):1929-1937.
[2] 贺丽英,孙蕴,要文娟,等.2010-2016年中国老年人骨质疏松症患病率Meta分析[J].中国骨质疏松杂志,2016,22(12):1590-1596.
[3] HIGGINS JP,THOMPSON SG,DEEKS JJ,et al.Measuring inconsistency in meta-analyses[J].BMJ,2003,327(7414):557-560.
[4] 姚新苗,杨林,王靖,等.益骨汤对去势大鼠血清激素水平、骨密度和骨生物力学影响的实验研究[J].中医正骨,2006,18(1):3-4.
[5] 中国老年学学会骨质疏松委员会,骨质疏松诊断标准学科组.中国人骨质疏松症建议诊断标准(第二稿)[J].中国骨质疏松杂志,2000,6(1):1-3.
[6] 中国老年学学会骨质疏松委员会中医药与骨病学科组.中医药防治原发性骨质疏松症专家共识(2015)[J].中国骨质疏松杂志,2015,21(9):1023-1028.
[7] 范文云,金海燕,徐美华.耳穴压豆配合太极拳运动对老年骨质疏松患者疼痛和骨密度的影响[J].中国中医药科技,2014,21(6):701-702.
[8] 蒋协远,王大伟.骨科临床疗效评价标准[M].北京:人民卫生出版社,2005:123-124.
[9] 郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:112-113.
[10] 张美娟.运动疗法对绝经期女性骨质疏松骨折的预防作用[J].中国老年学杂志,2013,33(9):2188-2189.
[11] 马艺璇,郭琪,侯安安,等.运动防治老年人骨质疏松的研究进展[J].中国骨质疏松杂志,2015,21(11):1385-1388.
[12] 郭宏焘.户外负重有氧运动结合局部肌力训练在老年骨质疏松预防中的效果研究[J].中国骨质疏松杂志,2015,21(8):941-944.
[13] HAGHIGHI A,SAMIMAGHAM H,GAHARDEHI G.Calcium and vitamin D supplementation and risk of kidney stone formation in postmenopausal women[J].Iranian Journal of Kidney Diseases,2013,7(3):210-213.
[14] KAWANO K,OGATA N,CHIANO M,et al.Klotho gene polymorphisms associated with bone density of aged postmenopausal women[J].Journal of Bone and Mineral Research,2002,17(10):1744-1751.
[15] ANDERST WJ,THORHAUER ED,LEE JY,et al.Cervical spine bone mineral density as a function of vertebral level and anatomic location[J].Spine Journal,2011,11(7):659-667.
[16] NORDEN BE,NEED AG, MORRIS MA,et al.The Nature and significance of the relationship between urinary sodium and urinary calcium in women[J].J Nutr,1993,123(9):1615-1622.
[17] ZHAO JG,ZENG XT,WANG J,et al.Association between Calcium or vitamin D supplementation and fracture incidence in Community-Dwelling older adults a systematic review and meta-analysis[J].JAMA,2017,318(24):2466-2482.
[18] 胡永红,李丽春,梁燕,等.中医药治疗肾阳虚型骨质疏松症研究进展[J].河北中医药学报,2012,27(4):42-43.
[19] 陈小香,邓伟民,魏秋实,等.从GH/IGF-1轴与PI3K/Akt通路探讨老年骨质疏松症的发病机制[J].中国骨质疏松杂志,2015,21(11):1412-1415.
[20] 金昊,金鑫,王文波.GH/IGF-1与骨质疏松的研究进展[J].中国矫形外科杂志,2015,23(5):431-433.

相似文献/References:

[1]谢冬群,黄中梁,叶金丽.加强隔附子饼灸治疗肾阳虚型腰椎间盘突出症的 临床研究[J].中医正骨,2015,27(09):18.
　XIE Dongqun,HUANG Zhongliang,YE Jinli.Clinical study on intensive aconite root cake separated moxibustion in the treatment of kidney-yang-deficiency-type lumbar disc herniation[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(11):18.
[2]李林军.应用膨胀式椎弓根螺钉内固定治疗合并骨质疏松的 胸腰椎退行性疾病[J].中医正骨,2015,27(08):49.
[3]韩艳,温利平,刘娜,等.补肾活血方对去卵巢大鼠骨代谢及骨密度的影响[J].中医正骨,2015,27(12):7.
　HAN Yan,WEN Liping,LIU Na,et al.Effect of Bushen Huoxue Fang(补肾活血方)on bone metabolism and bone mineral density in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(11):7.
[4]李学朋,朱立国.骨疏康胶囊对去卵巢大鼠骨小梁的影响[J].中医正骨,2015,27(12):12.
　LI Xuepeng,ZHU Liguo.Effect of Gushukang Jiaonang(骨疏康胶囊)on bone trabecula in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(11):12.
[5]陈冠军,陈扬,庄汝杰.可灌注骨水泥椎弓根螺钉系统 在老年腰椎疾患手术中的应用[J].中医正骨,2015,27(02):40.
[6]王丹辉,贲越,韩梅.林蛙油治疗绝经后骨质疏松症的临床研究[J].中医正骨,2014,26(01):27.
　Wang Danhui*,Ben Yue,Han Mei..Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(11):27.
[7]黄建华,黄建武,李慧辉,等.加味左归丸对绝经后骨质疏松症肝肾不足证 患者骨密度的影响[J].中医正骨,2013,25(11):19.
　Huang Jianhua*,Huang Jianwu,Li Huihui,et al.Effect of JIAWEI ZUOGUI pill on bone mineral density in postmenopausal osteoporosis patients with deficiency of liver and kidney[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(11):19.
[8]项旻,杨虹,林爱菊,等.绝经后2型糖尿病患者骨质疏松与血微量元素的关系研究[J].中医正骨,2013,25(12):20.
　Xiang Min*,Yang Hong,Lin Aiju,et al.Clinical study on the relationship between osteoporosis and serum trace elements levels in postmenopausal women with type 2 diabetes[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(11):20.
[9]史晓林,李春雯,张志强.弱阳离子磁珠分离技术和基质辅助激光解吸电离飞行时间质谱技术在原发性Ⅰ型骨质疏松症血清标志蛋白筛选中的应用[J].中医正骨,2014,26(03):5.
　Shi Xiaolin*,Li Chunwen,Zhang Zhiqiang..Application of magnetic beads based weak cation exchange separation technology and matrix-assisted laser desorption-ionization time of flight mass spectrometry technology in screening serum protein markers of primary type-Ⅰ osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(11):5.
[10]李明,徐明雄,冯左基,等.自拟壮骨方治疗绝经后骨质疏松症的疗效及作用机制研究[J].中医正骨,2014,26(09):21.
　Li Ming*,Xu Mingxiong,Feng Zuoji,et al.Study on the curative effect and mechanism of action of self-made ZHUANGGU decoction in treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(11):21.
[11]曹俊青,郑剑南,张麟.右归丸联合阿仑膦酸钠口服治疗绝经后骨质疏松症肾阳虚证的临床研究[J].中医正骨,2018,30(05):20.
　CAO Junqing,ZHENG Jiannan,ZHANG Lin.A clinical study of oral application of Yougui Wan(右归丸)and alendronate sodium for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(11):20.
[12]李中万,徐绍俊,杨广钢,等.健肾方联合碳酸钙D3咀嚼片(Ⅱ) 治疗绝经后骨质疏松症肾阳虚证[J].中医正骨,2018,30(08):11.
　LI Zhongwan,XU Shaojun,YANG Guanggang,et al.Oral application of Jianshen Fang(健肾方)and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ)for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(11):11.
[13]汪青,黄昊强,陈勇,等.二仙汤在绝经后骨质疏松症肾阳虚证治疗中的应用价值及作用机制研究[J].中医正骨,2022,34(03):8.
　WANG Qing,HUANG Haoqiang,CHEN Yong,et al.Applied values and mechanism of action of oral application of Erxian Tang(二仙汤)in treatment of postmenopausal osteoporosis with syndrome of kidney-yang deficiency:a clinical study[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2022,34(11):8.
[14]黄晨,施杞,王拥军,等.基于代谢组学技术探讨肾阳方治疗骨质疏松症肾阳虚证的作用机制[J].中医正骨,2023,35(09):1.
　HUANG Chen,SHI Qi,WANG Yongjun,et al.A study of mechanism of Shenyang Fang(肾阳方)in treatment of osteoporosis with syndrome of kidney-yang deficiency based on metabonomics technology[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2023,35(11):1.
[15]李超,张贤,马勇,等.补髓丹治疗骨质疏松症肾阳虚证的随机对照临床试验[J].中医正骨,2024,36(12):24.
　LI Chao,ZHANG Xian,MA Yong,et al.Busui Dan(补髓丹)in the treatment of osteoporosis with syndrome of kidney-yang deficiency:a randomized controlled trial[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2024,36(11):24.

备注/Memo

备注/Memo:
基金项目:浙江省中医药科技计划项目(2017ZA071)
通讯作者:何帮剑 E-mail:69554628 @qq.com
更新日期/Last Update: 2018-11-30